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Purpose: We evaluated the progression rate of total, and upper and lower visual field defects 
in treated open-angle glaucoma patients.
Patients and methods: This study was a retrospective, nonrandomized, comparative study. 
Five-hundred forty-four eyes from 315 Japanese open-angle glaucoma patients were examined. 
The mean deviation (MD) and total deviation (TD) for both the upper and lower slopes on the 
Humphrey Field Analyzer were calculated and compared in high-tension glaucoma (.21 mmHg) 
and normal-tension glaucoma (#21 mmHg).
Results: Patients with over −20 dB of MD and over −23 dB of upper or lower TD were 
enrolled into each analysis. Patients with −7.75 ± 5.30 (mean ± standard deviation) dB of MD, 
−9.16 ± 10.80 dB of upper TD, or −7.11 ± 6.02 dB of lower TD were followed up for 4–19 years. 
The mean MD slope was −0.41 ± 0.50 dB/year, the upper TD slope was −0.46 ± 0.65 dB/year, 
and the lower TD slope was −0.32 ± 0.53 dB/year. Comparing high-tension glaucoma and 
normal-tension glaucoma, the upper TD slope was similar for both types of glaucoma, but 
the MD and lower TD slopes in high-tension glaucoma were significantly lower than those in 
normal-tension glaucoma.
Conclusions: The progression rates in lower visual field defects in high-tension glaucoma 
might be faster than those in normal-tension glaucoma. The results of this study might be used 
to predict the prognosis of visual field defects, as well as the quality of vision in patients with 
open-angle glaucoma.
Keywords: open-angle glaucoma, visual field defects, progression rate, primary open-angle 
glaucoma, normal-tension glaucoma
Introduction
Glaucoma is one of the leading causes of acquired blindness worldwide.1,2 A lot of 
clinical trials have confirmed the importance of intraocular pressure (IOP) in the devel-
opment of open-angle glaucoma and its progression. These studies have shown that IOP 
reduction lessens the risk of development and progression of open-angle glaucoma.3–14 
In the Ocular Hypertension Treatment Study (OHTS),3,4 the mean reduction of IOP 
in the treated group was 22.5% ± 9.9% (mean ± standard deviation [SD]). The IOP 
decreased by 4.0% ± 11.6% in the observation group. Treatment to reduce IOP also 
reduced the progression of clinically manifest glaucoma from 62% to 45% in the 
Early Manifest Glaucoma Trial (EMGT),5–7 and from 27% to 12% in the Collaborative 
Normal Tension Glaucoma Study (CNTGS).8–10 In addition, these multicenter trials 
identified various clinical factors related to both the onset or progression of glaucoma. Clinical Ophthalmology 2010:4
Table 1 The profiles of the patients enrolled into the study
OAG  HTG NTG P
Patients (eyes/cases) 544/325 265 /154 279/171
Bilateral/unilateral (cases) 219/106 111/43 108/63
OD/Os (eyes) 273/271 138/127 135/144
gender
  Male (eyes/cases) 236/141 132/77 104/64 
  Female (eyes/cases) 308/184 133/77  175/107 
Age (years) 57.2 ± 11.3 
(30–79)
57.1 ± 11.3 
(33–79)
57.3 ± 10.7 
(30–79)
0.9974
Follow-up duration (years) 8.78 ± 4.01 
(4–19)
8.78 ± 4.01 
(4–18)
9.06 ±3.71 
(4–19)
0.0526
initial MD (dB) −9.50 ± 8.75 
(−0.01 to −31.7)
−10.46 ± 8.75 
(−0.03 to −31.7)
−8.59 ± 6.12 
(−0.01 to −27.1)
0.0326
initial upper TD (dB) −11.80 ± 9.35 
(−0.18 to −30.95)
−12.54 ± 9.35 
(−0.18 to −30.95)
−11.09 ± 8.30 
(−0.43 to −28.9)
0.0464
initial lower TD (dB) −8.35 ± 9.73 
(−0.97 to −31.12)
−9.28 ± 9.73 
(−0.97 to −31.12)
−7.46 ± 6.52 
(−0.97 to −30.55)
0.0932
Note: By Mann–Whitney’s U-test.
Abbreviations: OAG, open-angle glaucoma; HTG, high-tension glaucoma; NTG, normal-tension glaucoma; MD, mean deviation; TD, total deviation. 
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However, the pathogenesis of glaucomatous optic neuropathy 
and its long-term progression are still unknown.
Patients with open-angle glaucoma, primary open-angle 
glaucoma, and normal-tension glaucoma require man-
agement and follow-up in the long term, and essentially 
for a lifetime. Thus, with longer-term follow-up, we can 
understand more about the disease course of open-angle 
glaucoma. The treatment for glaucoma, ie, lowering of 
IOP, is not free from risk.15,16 We have to achieve a balance 
between treatment intensity and disease severity, such as 
stage of glaucoma, life expectancy, and rate of progression. 
Over two decades have passed since standard automated 
perimetry was introduced into clinical practice for the man-
agement and monitoring of glaucoma. A lot of clinical data 
from glaucomatous patients have been accumulated using 
standard automated perimetry. The results of multicenter 
trials have set a number of different criteria and scoring 
methods to evaluate progression of glaucomatous visual 
field defects.3–14,17–31 When the visual field defect crossed the 
criteria or the scores increased, it was judged as progression. 
We can therefore understand the prevalence of progressive 
cases. Although there are rare cases of rapid progression, 
open-angle glaucoma progresses slowly, but exactly, as seen 
in careful examination over a 10-year period in general.9 The 
progression rate of visual field defects should be known so 
that advances in the management and treatment of open-
angle glaucoma can be evaluated.
The primary purpose of treatment for glaucoma is to 
maintain the patient’s quality of life and quality of vision. 
The severity of the condition of the visual field should be 
calculated in each patient and the expected progressive 
rate of the visual field defects. Glaucomatous visual field 
has a character to change by upper and lower segments 
independently. We have been able to analyze the area and 
progression of visual field defects by total fields as well 
as by upper and lower visual fields separately. From the 
standpoints of quality of life and quality of vision, the lower 
visual field is more susceptible to subjective symptoms.32–35 
When we evaluate the severity and the progression of the 
glaucomatous visual field defects, we have to precede the 
lower visual field.
In this study we evaluated the progression rate of the 
total as well as the upper and lower visual field defects 
separately from a series of standard automated perimetry 
results of open-angle glaucoma patients who had been 
managed and followed up in the middle to long term for 
up to 19 years. Furthermore, we classified open-angle 
glaucoma into higher and lower IOP groups and compared 
these two groups.
Patients and methods
Patient selection
A total of 323 open-angle glaucoma patients (544 eyes) 
from the Ophthalmology Clinic at the Niigata University 
Medical and Dental Hospital were recruited according to the 
following inclusion and exclusion criteria. Overall profiles 
of the patients are shown in Table 1. We separated open-
angle glaucoma patients into two groups according to their 
maximum IOP, ie, high-tension glaucoma (. 21 mmHg) and 
normal-tension glaucoma (#21 mmHg).Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1317
Visual field defect progression in OAG
inclusion criteria
•	 A diagnosis of primary open-angle glaucoma or normal-
tension glaucoma based on clinical examinations by 
slit lamp, optic disc, and visual field with the normal 
anterior chamber angle. Clinical diagnosis of each 
glaucoma type was according to the guidelines of the 
European Glaucoma Society36 and the Japan Glaucoma 
Society37
•	 Ages at the initial examination between 30 and 80 years
•	 Follow-up for at least four years with reliable (fix loss, 
pseudopositive, and negative, less than 30%) results at 
least five times by the Humphrey Field Analyzer (Carl 
Zeiss Medthec Inc., Dublin, CA) using the Full-Threshold 
30-2 program
•	 Reproducible glaucomatous visual field defects by 
Anderson and Patella’s criteria38 and mean devia-
tion (MD) 0 dB or lower both at the initial and final 
examinations.
When glaucoma surgery was performed, follow-up was 
ended or started at that time point. A longer duration of 
follow-up either before or after surgery was chosen for this 
study as following the same criteria. Cataract surgery was 
permitted, but if the IOP or visual field changed significantly 
before or after the surgery, we used the same approach as for 
the glaucoma surgery.
exclusion criteria
•	 Refractive errors (spherical equivalent power less 
than −6 D or more than +6 D)
•	 Corrected visual acuity under 20/40
•	 Combination with cataract, which possibly influences 
the visual acuity and visual field. Eyes with reduction 
of three or more steps in corrected visual acuity due to 
cataract progression were excluded
•	 Overlap of other types of glaucoma, such as primary 
angle-closure glaucoma, pseudoexfoliation glaucoma, 
and steroid-induced glaucoma. Cases with a shallow 
anterior chamber under Grade 2 or a van Herick’s or 
Shaffer’s classification were excluded
•	 Combination of congenital optic disc anomalies (tilted 
disc syndrome, optic nerve hypoplasia, optic disc pit, or 
coloboma) or retinal diseases (diabetic retinopathy, retinal 
vein or artery occlusion, acquired macular degeneration, 
central serous chorioretinopathy)
•	 Possibility of other optic nerve disease (eg, optic neuritis, 
anterior ischemic optic neuropathy)
•	 Intracranial lesions or trauma possibly associated with 
visual field defects.
study visit
Patients were observed every three months. The study 
visits included IOP measurements with the Goldmann 
Applanation Tonometer. Perimetry was performed with 
the Humphrey Field Analyzer using the Full-Threshold 
30-2 program at least once a year. Patients also underwent 
best-corrected visual acuity measurements and a standard 
eye examination including slit-lamp and ophthalmoscopic 
examinations.
Analysis of visual field
The progressive rate of the total visual field defect was 
evaluated by the MS slope on the Humphrey Field Analyzer. 
Those of the upper and lower visual field defects were also 
evaluated using the upper and lower total deviation slopes 
(upper TD slope and lower TD slope). A linear regression 
analysis was performed by a Windows-based PC program, 
HfaFiles ver.5 (Beeline Office Co., Tokyo), to calculate 
the MD slope, and the upper and lower TD slope. The first 
two or three visual field results were excluded in order 
to minimize learning effects. No reliable, unexpected, or 
unreasonable results were excluded. From our preliminary 
study using the same patients, the MD slope as well as 
the TD slope might not be suitable for the analysis of the 
progressive rates in cases with severe visual field defects. 
Thus, we excluded eyes with an initial MD under −20 dB 
and an initial upper or lower TD under −23 dB from each 
examination.
Visual field progression
Progression analysis for glaucomatous visual field using a 
statistical linear regression analysis has been called trend-
type analysis.39 In eyes associated with a significant negative 
correlation against time progress statistically, it is decided as 
progression in this system. So when the eyes had a negative 
value (,0 dB/year) for MD slope, and upper or lower TD 
slope, and a P value under 5%, in the study they were eyes 
with statistically significant progression. The cases were 
included in the group of “statistical progression” in this study. 
The exact evaluation using the trend-type analysis requires 
more visual field examinations in the longer term than that 
of the event analysis. If the visual field results were too vari-
able, it was often hard to evaluate as statistically significant 
progression, even with long-term follow-up or rapid progres-
sion. Thus, we set different criteria for the progression, ie, 
“rapid progression” for the MD slope, and upper or lower 
TD slope under -1.0 dB/year, and “moderate progression” 
for those under -0.5 dB/year.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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statistical analysis
The Chi-square test was used for the comparison of gender, 
sides affected, and prevalence of “statistical progression”, 
“rapid progression”, or “moderate progression” between 
high-tension glaucoma and normal-tension glaucoma. Mean 
age, follow-up duration, follow-up IOP, MD, upper and lower 
TD at initial examination, MD slope, and upper and lower 
TD slope were compared between high-tension glaucoma and 
normal-tension glaucoma using the Mann–Whitney U-test.
Results
Finally, 485 eyes from 305 cases for the MD slope, 458 
eyes from 293 cases for the upper TD slope, and 510 eyes 
from 302 cases for the lower TD slope were enrolled in the 
analysis from the initial 544 eyes from 325 cases with open-
angle glaucoma (Tables 2, 3, and 4). Although the initial MD 
was −7.75 ± 5.30 (mean ± SD) dB at 57.3 ± 10.8 years, the 
visual field defects progressed with −0.41 ± 0.50 db/year of 
the MD slope during 8.91 ± 3.80 years of follow-up. The 
initial upper TD was −9.16 ± 10.8 dB and the upper TD slope 
was −0.46 ± 0.65 dB/year. Instead, the lower TD slope was 
−0.32 ± 0.53 dB/year during 8.80 ± 3.77 years of follow-up 
from −7.11 ± 6.02 dB of the initial lower TD.
The frequency distribution of the MD slope for high-
tension glaucoma and normal-tension glaucoma is shown in 
Figure 1A. In both the high-tension glaucoma and normal-
tension glaucoma groups, eyes with an MD slope between 0 
and −0.5 dB/year were seen most frequently. The frequency 
of an MD slope between 0 and −0.5 dB/year was greater in 
normal-tension glaucoma than in high-tension glaucoma. 
In the cases studied for MD slope evaluation, the mean 
follow-up term; initial age; initial MD; MD slope; and 
number of eyes with statistical progression, rapid progres-
sion, or moderate progression in open-angle glaucoma, 
high-tension glaucoma, and normal-tension glaucoma are 
shown in Table 2. There was no statistically significant dif-
ference in mean follow-up duration and initial MD between 
high-tension and normal-tension glaucoma. The prevalence 
of statistical progression was similar between the two 
groups. However, the mean MD slope was lower and there 
were more eyes with moderate or rapid progression in the 
high-tension glaucoma group than in the normal-tension 
glaucoma group.
The frequency distribution of the upper TD slope with 
high-tension and normal-tension glaucoma is shown in 
  Figure 1B. The upper TD slope was from over 0.5dB/year 
to under −3dB/year, so it was distributed in a wider range 
than for those of the MD slope and lower TD slope. Com-
paring the MD slope and the lower TD slope, it was signifi-
cant that the frequency of the upper TD slope was greater 
in normal-tension glaucoma (from −1.0 to −2.0 dB/year) 
than in high-tension glaucoma (Table 3). For the upper TD 
slope, the results for mean follow-up duration, initial upper 
TD, TD slope, and the prevalence of statistical progression, 
rapid progression, and moderate progression were quite 
similar between high-tension glaucoma and normal-tension 
glaucoma.
The frequency distribution of the lower TD slope is pre-
sented in Figure 1C. Distribution of the lower TD slope was 
quite similar to that of the MD slope. As with the MD slope, 
there were no statistical differences in the mean follow-up 
term and initial lower TD between high-tension glaucoma 
Table 2 The profiles of the patients enrolled into mean deviation (MD) slope analysis and the results. (mean ± standard deviation 
and range)
MD slope OAG HTG NTG P
Patient (eyes/cases) 485/305 221/131 264/174
Age at initial examination (years) 57.3 ± 10.8 
(30–79)
57.4 ± 10.8 
(33–79)
57.3 ± 10.8 
(30–79)
0.70891
Follow-up term (years) 8.91 ± 3.80 
(4–19)
8.60 ± 3.86 
(4–18)
9.17 ± 3.73 
(4–19)
0.06461
initial M D(dB) −7.75 ± 5.30 
(−0.03 to −19.80)
−7.65 ± 5.21 
(−0.03 to −19.41)
−7.83 ±5.37 
(−0.01 to −19.80)
0.78941
Follow-up IOP (mmHg) 15.1 ± 2.73 
(7.4–24.2)
16.9 ± 2.56 
(8.2 −24.2)
13.6 ± 1.80 
(7.4–17.7)
0.00001
MD slope (dB/year) −0.41 ± 0.50 
(+1.05 to −2.42)
−0.49 ± 0.59 
(+1.05 to −2.42)
−0.35 ± 0.41 
(+0.59 to −1.96)
0.03291
Significant progression (eyes) 227 (46.8%) 97 (43.9%) 130 (49.2%) 0.23952
Moderate progression (#−0.5 dB/year, eyes) 166 (34.2%) 89 (40.2%) 78 (29.5%) 0.01332
rapid progression (#−1.0 dB/year, eyes) 52 (10.7%) 35 (15.8%) 19 (7.1%) 0.00262
Notes: 1By Mann–Whitney’s U-test; 2 By Chi-square test.
Abbreviations: OAG, open-angle glaucoma; HTG, high-tension glaucoma; NTG, normal-tension glaucoma; MD, mean deviation; TD, total deviation; IOP, intraocular pressure. Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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and normal-tension glaucoma (Table 4). The mean lower TD 
slope was lower and there were more eyes with rapid and 
moderate progression in the high-tension glaucoma group 
than in the normal-tension glaucoma group. The prevalence 
of statistical progression was similar between the groups.
Discussion
In this study we retrospectively evaluated the rate of progres-
sion of visual field defects in Japanese open-angle glaucoma 
patients whom we followed in the middle to long term for 
up to 19 years. Many previous studies, including multicenter 
trials, had evaluated the progression of glaucomatous visual 
field defects by setting the criteria or grading to be used for the 
duration of follow-up.3–14,17–27 In general, life-table analysis 
was used in these studies to reflect the rate of progression. 
The present study evaluated the progression rate directly, so 
it is different from a number of previous investigations. In 
addition, we analyzed eyes separately using total, and upper 
and lower visual fields. No similar studies were identified in 
a literature search.
Trend-type analysis39 and event-type analysis40,41 are 
known to be two representative methods for detecting or 
evaluating glaucomatous visual field defect progression using 
standard automated perimetry. Trend-type analysis using the 
MD slope or TD slope can show the progression trend more 
exactly, as well as the progression rate or speed of the visual 
field defect. Mean progression rate of the total visual field 
in open-angle glaucoma patients was −0.41 dB/year in the 
Table 3 The profiles of the patients enrolled into upper total deviation (upper TD) slope analysis and the results. (mean ± standard 
deviation and range)
Upper TD slope OAG  HTG NTG P
Patients (eyes/cases) 458/293 210/127 248/166
Age at initial examination (years) 57.1 ± 10.6 
(30–79)
57.2 ± 10.6 
(33–74)
57.1 ± 10.7 
(30–79)
0.74651
Follow-up duration (years) 8.88 ± 3.81 
(4–19)
8.57 ± 3.86 
(4–18)
9.13 ± 3.77 
(4–19)
0.08451
initial upper TD (dB) −9.16 ± 10.8 
(−0.18–22.97)
−9.00 ± 6.30 
(−0.18–22.97)
−9.29 ± 6.94 
(−0.43 to −22.97)
0.97121
Follow-up IOP (mmHg) 15.0 ± 2.76 
(6.1–24.2)
16.7 ± 2.77 
(6.1–24.2)
13.6 ± 1.78 
(7.4–17.7)
0.00001
Upper TD slope (dB/year) −0.46 ± 0.65 
(+0.85 to −3.62)
−0.51 ± 0.75 
(+0.84 to −3.62)
−0.41 ± 0.55 
(+0.85 to −3.05)
0.55211
Significant progression (eyes) 191 (41.7%) 83 (39.5%) 108 (43.5%) 0.38412
Moderate progression (#−0.5 dB/year, eyes) 165 (36.0%) 84 (40.0%) 81 (32.6%) 0.10312
rapid progression (#−1.0 dB/year, eyes) 81 (17.6%) 42 (20.0%) 39 (15.7%) 0.23232
Notes: 1By Mann–Whitney’s U-test; 2By Chi-square test. 
Abbreviations: OAG, open-angle glaucoma, HTG, high-tension glaucoma; NTG, normal-tension glaucoma; MD, mean deviation; TD, total deviation.
Table 4 The profiles of the patients enrolled into the lower total deviation (lower TD) slope analysis and the results. (mean ± standard 
deviation and range)
Lower TD slope OAG  HTG NTG P
Patient (eyes/cases) 510/302 238/135 272/167
Age at initial examination (years) 57.6 ± 10.8 
(30–79)
57.7 ± 10.8 
(33–79)
57.5 ± 10.7 
(30–79)
0.67931
Follow-up term (years) 8.80 ± 3.77 
(4–19)
8.48 ± 3.82 
(4–18)
9.09 ± 3.72 
(4–19)
0.05321
initial lower TD (dB) −7.11 ± 6.02 
(−0.97 to −22.79)
−7.31 ± 6.21 
(−0.97 to −22.79)
−6.98 ± 5.85 
(−0.97 to −22.64)
0.89911
Follow-up IOP (mmHg) 15.0 ± 2.78 
(3.9–24.2)
16.7 ± 2.69 
(3.9–24.2)
13.5 ± 1.86 
(5.9–17.4)
0.00001
Lower TD slope (dB/year) −0.32 ± 0.53 
(+1.14 to −3.64)
−0.40 ± 0.64 
(+1.14 to −3.65)
−0.25 ± 0.39 
(+0.57 to −1.84)
0.03921
Significant progression (eyes) 186 (36.4%) 88 (36.9%) 98 (36.0%) 0.82492
Moderate progression (#−0.5 dB/year, eyes) 131 (25.6%) 76 (31.9%) 55 (20.2%) 0.00252
rapid progression (#−1.0 dB/year, eyes)  42 (8.2%) 27 (11.3%) 15 (5.5%) 0.01692
Notes: 1By Mann–Whitney’s U-test; 2By Chi-square test. 
Abbreviations: OAG, open-angle glaucoma, HTG, high-tension glaucoma; NTG, normal-tension glaucoma; MD, mean deviation; TD, total deviation.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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MD slope. This indicates that it would take 25 years for a 
decrease of 10 dB in standard automated perimetry to occur 
if the cases progressed at a similar rate. Although the prog-
nosis might be better for patients diagnosed at an early stage, 
patients with a middle or late stage of visual field defect might 
have to expect subjective impairment during their lifetime. 
Comparing high-tension and normal-tension glaucoma, those 
with high-tension glaucoma progressed faster than those with 
normal-tension glaucoma. Progression in the upper visual 
field was faster than that in the lower visual field, and this 
phenomenon was more marked in normal-tension glaucoma. 
Although the progression rate in the upper visual field was 
similar between high-tension and normal-tension glaucoma, 
the progression rate in the lower visual field was slower in 
normal-tension glaucoma than that in high-tension glaucoma. 
Thus, the difference in progression rate for the total visual 
field between high-tension and normal-tension glaucoma 
might depend on the difference in the lower visual field.
EMGT5–7 is a study that included patients with IOP # 
30 mmHg and −16 dB or better of MD who were similar to 
those in our study. Heijil et al7 reported that −0.05 dB/month 
in MD slope without treatment increased to −0.03 dB/month 
with treatment. On the other hand, the CNTGS reported 
that the MD slope in normal-tension glaucoma cases was 
−0.41 dB/year without treatment.9 Another report from the 
CNTGS evaluated the benefits of lowering IOP by various 
background factors using the MD slope.10 Although the MD 
slopes in untreated cases were about between −0.35 and 
−0.6 dB/year, those in treated cases improved at a rate of 
around −0.2 to −0.35 dB/year. Treated MD slopes from both 
the EMGT and CNTGS appear similar to our results.
The disadvantages of trend-type analysis are that it is 
possible that local progression in the visual field can be 
disclaimed by general stability, and that this analysis needs 
a longer follow-up duration and more field examinations 
than event-type analysis for correct assessment. Although 
the patients with good reliability and reproducibility can 
be evaluated for statistical progression over shorter peri-
ods, others are often hard to evaluate, even with long-term 
follow-up. Therefore, we set three different criteria for 
visual field progression, ie, statistical progression (MD 
slope , 0 dB/year and P , 0.05), moderate progression 
(MD slope # −0.5 dB/year), and rapid progression (MD 
slope # −1.0dB/year). Statistically significant progression 
was detected in 47.2% in total, and 40.8% in upper and 37.3% 
in lower visual fields. There was no difference between 
high-tension glaucoma and normal-tension glaucoma. The 
cases of 10.1% in total, 16.1% in upper, and 7.9% in lower 
visual fields were classified as rapid progression. With 
regard to total and lower visual fields, fewer normal-tension 
glaucomatous eyes showed rapid progression than eyes with 
high-tension glaucoma. Eyes with moderate progression 
comprised 33.6% in total, with 32.6% of upper and 25.9% 
of lower visual fields. In summary, the progression rates in 
the upper visual field might be faster than those in the lower 
visual field, and the progression rate of total and lower visual 
fields with high-tension glaucoma might be faster than in 
those with normal-tension glaucoma.
Several previous studies have discussed the similari-
ties and differences between visual field defects associated 
with primary open-angle glaucoma and normal-tension 
glaucoma.28–31,42–44 Glaucomatous visual field defects are 
often identified in the upper field, both in primary open-angle 
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Figure 1 Frequency distributions of mean deviation (MD) slope A), upper total 
deviation (upper TD) slope B) and lower total deviation (lower TD) slope C) in the 
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glaucoma and normal-tension glaucoma.42–45 Araie et al29 
reported that an area just above the horizontal meridian was 
  significantly more depressed in normal-tension glaucoma, 
whereas high-tension glaucoma had significantly more 
  diffuse visual field damage. Caprioli and Spaeth30 showed 
that scotoma in the low-tension group had a steeper slope, 
was significantly closer to the fixation, and had greater depth 
than in those from the high-tension group. Chauhan et al31 
mentioned that individuals with normal-tension glaucoma 
had larger areas with normal sensitivity, and hence more 
localized damage. With progression, normal-tension glau-
coma in the early stage trends towards local depression, 
particularly in the upper central and upper nasal visual fields. 
Thus, although it has been recognized that both primary open-
angle glaucoma and normal-tension glaucoma have a similar 
progression pattern, the visual field defect is often seen in 
a more localized upper area with normal-tension glaucoma, 
but generally in a more diffuse area with primary open-
angle glaucoma. Our results might confirm the difference 
in visual field defect between primary open-angle glaucoma 
and normal-tension glaucoma in terms of progression rate. 
The issue of whether normal-tension glaucoma is different 
from primary open-angle glaucoma remains a matter of 
debate. We cannot distinguish between primary open-angle 
glaucoma and normal-tension glaucoma exactly on the basis 
of IOP, because individual IOP is variable. In this study, 
we separated high-tension glaucoma and normal-tension 
glaucoma according to the maximum recorded IOP, so both 
high-tension glaucoma and normal-tension glaucoma groups 
must include overlap or immediate cases. Nevertheless, the 
results showed weak but significant differences between 
normal-tension glaucoma and high-tension glaucoma in the 
progressive nature of visual field defects.
The results of this study might be useful when considering 
the visual prognosis in open-angle glaucoma. Recently, some 
research has been done on the relationship between visual 
field defects and quality of vision (QOV) in glaucomatous 
patients.32–35 Lower visual field defects, particularly in the 
central visual field, are closely related to subjective symptoms 
as well as to QOV.
Generally, visual field defects under −20 dB of MD by 
Humphrey Field Analyzer influence to the worse for visual 
subjective. Almost all cases under −25dB of MD are incon-
venienced, and this level is sometimes called functional 
blindness. We have to maintain the aim for each individual 
glaucomatous patient to not reach visual impairment during 
their lifetime. We always have to take into account in our 
clinical practice how much progression we can permit and 
how much we must prevent. Evaluation of the progression 
rate of visual field defects, particularly in the upper and 
lower fields, taking into account area, degree of defect, and 
age is necessary for the effective and safe management of 
open-angle glaucoma patients.
This study is important because it includes a large amount 
of clinical information from a big group of open-angle glau-
coma patients, with long-term follow-up. However, the study 
does have some limitations. Faster and more progressive cases 
may have been missed at the enrolment of study patients. In 
a report from the CNTGS,9 the fast progressive eye under 
−1.0 dB/year were quite a few in the eyes with more than 
three years of follow-up of treatment. The cases over 0 dB 
were hard to calculate for the MD slope or TD slope even if 
they satisfied Anderson and Patella’s glaucoma criteria. Cases 
under −20 dB of MD or under −23 dB of upper or lower 
TD were also excluded. These cases were too severe for the 
progression rate to be evaluated by MD slope or TD slope 
from preliminary examination. Fortunately, the clinical back-
grounds in the finally selected cases were similar between 
the high-tension glaucoma and normal-tension glaucoma 
patients. Therefore, the results indicate that high-tension 
glaucoma and normal-tension glaucoma might be differ-
ent in progression rate for the total and lower visual fields. 
Furthermore, this study included patients followed up from a 
long time ago. The eyedrops used, as well as treatment targets, 
were different from the more recent research.43 We have to 
consider that the results may not reveal the prognosis of the 
patients whom we are presently managing and following up. 
Information about patient backgrounds and other factors, 
including general history, central corneal thickness, and disc 
hemorrhage, was incomplete because of the retrospective 
nature of the study. The complete exclusion of cataract-
associated cases whose visual field results were influenced 
would be difficult. In particular, the analysis of upper and 
lower visual fields must be influenced by using the TD as in 
this study. All cases with repeated glaucoma surgery that are 
too variable for follow-up IOP or with unreliable visual field 
results were also excluded. In addition, we had not set treat-
ment targets for this study. We have had to take these factors 
into consideration when interpreting our results.
Using the same patients, we determined that high-
tension glaucoma and normal-tension glaucoma have a 
weak but statistically significant correlation between IOP 
and the progression rate of visual field defects. This means 
that the higher the IOP, the faster the progression of visual 
field defects. The differences in progression rate between 
high-tension glaucoma and normal-tension glaucoma were Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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reasonable in the lower field. The similarity in the upper 
visual field may be incompatible. In a further investigation, 
we are examining the relationship between rate of visual field 
defect progression and follow-up IOP, and IOP reduction and 
related factors in the upper and lower visual fields. Improved 
medication in glaucoma has definitely resulted in lower 
follow-up IOP.45 Also, the progression rate of visual field 
defects in open-angle glaucoma patients may have altered 
from 10 years ago. We can confirm the true improvement in 
glaucoma therapy by evaluation of IOP, as well as suppres-
sion of progressive rate.
Although this study showed the managed course of open-
angle glaucoma patients rather than the natural history of 
progression, it gives us a better understanding of the disease 
course and its progression, evaluation of long-term treatment, 
and likely prognosis in open-angle glaucoma.
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